Search - tctmd.com

June 29, 2016

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

June 14, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

June 14, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

June 14, 2016

News Daily News

研究显示糖尿病患者急性心梗后风险差异很大

May 26, 2016

News Daily News

Un Estudio Revela un Sorprendente Rango de Riesgo Post-IAM entre Pacientes con Diabetes

May 26, 2016

News Daily News

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

May 26, 2016

News Daily News

尽管有指南说明，但糖尿病患者多支 CAD 患者接受 PCI 的人数仍多于 CABG

May 13, 2016

News Daily News

Guidelines Notwithstanding, More Diabetics with Multivessel CAD Receive PCI Than CABG

May 13, 2016

News Daily News

A Pesar de las Directrices, Más Diabéticos con EAC Multivaso son sometidos a PCI que a CABG

May 13, 2016

News Industry News

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

May 06, 2016

News Daily News

糖尿病患者（即使需要胰岛素）中依维莫司支架优于紫杉醇支架：TUXEDO 分析

April 25, 2016

News Daily News

Everolimus Stent Better Than Paclitaxel Stent in Diabetic Patients, Even Those Requiring Insulin: TUXEDO Analysis

April 25, 2016

News Daily News

Análisis del TUXEDO: Los Stents de Everolimus son Mejores que los de Paclitaxel en Pacientes Diabéticos, Incluso en Insulinodependientes

April 25, 2016

News Daily News

越来越多证据显示以肠促胰岛素类降糖药不会增加心衰风险

March 25, 2016

News Daily News

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

March 25, 2016

News Daily News

Cada Vez Más Evidencias Confirman que No hay un Mayor Riesgo de Insuficiencia Cardíaca asociado a los Fármacos Antidiabéticos basados en la Incretina

March 25, 2016

News Industry News

Victoza® Significantly Reduced the Risk of Major Adverse Cardiovascular Events in the LEADER Trial

March 06, 2016

News Industry News

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

March 01, 2016

News Daily News

糖尿病对 DES 治疗的患者的影响甚于病变复杂性